Predicting Recurrence of Stage IA Lung Adenocarcinoma Using Circulating Tumor Cell-Free DNA Whole-Genome Mutational Signatures.

Although for stage IA, lung adenocarcinoma surgery is often curative, recurrence rates remain significant.

Liquid biopsy enables monitoring residual disease and predicts recurrence; however, utility in stage IA lung adenocarcinoma is not well established.

Tumor was sequenced at 40× and germline DNA and plasma derived ctDNA at 20×, and patient-specific mutational signatures were developed from the tumor-normal comparison and applied to ctDNA whole-genome sequencing at each time point using an artificial intelligence-supported pattern recognition algorithm. ctDNA results were compared with clinical recurrence.